当前位置： SCI文献检索 > Clinical Breast Cancer期刊下所有文献 > Breast cancer stem cells: a novel therapeutic target.

Breast cancer stem cells: a novel therapeutic target.

Abstract：

:Breast cancer stem cells (BCSCs), characterized by the CD44(+)/CD24(-/low) marker, are attributed with features that are demonstrated by the disease itself, such as growth of tumor, recurrence, metastases, and multiple drug resistance. This review concerns the emergence and expediency of BCSCs in treating relapse and advanced cases of breast cancer. One of the ideal ways of detecting and eliminating BCSCs would be to tweak certain molecular receptors in the desired pathway, which would require extensive and comprehensive knowledge about these cell signaling pathways. Although hedgehog (Hh), Notch, and Wnt signaling are of prime concern, governing tumorigenesis and cancer stem cell (CSC) renewal, designing chemotherapeutic or molecular targeted therapies is still a tricky arena to venture into, as these pathways play a vital role in normal mammary gland development. Thus selective inhibition of pathway receptors needs to be investigated in the future.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Gangopadhyay S,Nandy A,Hor P,Mukhopadhyay A

doi

10.1016/j.clbc.2012.09.017

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

7-15

issue

1

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(12)00221-2

journal_volume

13

pub_type

杂志文章,评审

相关文献

Clinical Breast Cancer文献大全
  • Dietary Patterns and Risk of Invasive Ductal and Lobular Breast Carcinomas: A Systematic Review and Meta-analysis.

    abstract：:The histopathologic subtypes of breast cancer, including invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), differ in terms of risk factors, progression, and response to treatment. The PubMed/Medline, Web of Science, and Scopus databases were searched up to February 2020 for published studies on the...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2020.03.007

    authors： Dianatinasab M,Rezaian M,HaghighatNezad E,Bagheri-Hosseinabadi Z,Amanat S,Rezaeian S,Masoudi A,Ghiasvand R

    更新日期：2020-08-01 00:00:00

  • Adjuvant therapy in elderly patients with breast cancer.

    abstract：:The elderly population has been neglected by the traditional approach to clinical breast cancer research. Elderly women have been underrepresented in breast cancer clinical trials, with the majority of studies being restricted to patients aged < 70 years. Elderly patients frequently have comorbidities and/or impaired ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2004.n.022

    authors： Biganzoli L,Aapro M,Balducci L,Crivellari D,Minisini A,Piccart M

    更新日期：2004-08-01 00:00:00

  • Evaluation of Multifocality and Multicentricity With Breast Magnetic Resonance Imaging in Each Breast Cancer Subtype.

    abstract：INTRODUCTION:The purpose of this study was to evaluate whether diagnostic performance of breast magnetic resonance imaging (MRI) for detection of multifocality and multicentricity (MFMC) of breast cancer (BC) can be influenced by different histotypes or immunophenotypes in newly diagnosed patients with breast cancer. ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.10.012

    authors： Prochowski Iamurri A,Ponziani M,Macchini M,Fogante M,Pistelli M,De Lisa M,Berardi R,Giuseppetti GM

    更新日期：2018-04-01 00:00:00

  • Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.

    abstract：BACKGROUND:The prognostic/predictive value of aberrant MYC gene copies and protein expression is not clear in breast cancer. PATIENTS AND METHODS:Early breast cancer patients were treated with anthracycline-containing chemotherapy within 2 randomized adjuvant trials. MYC gene and centromere-8 status, as well as Myc pr...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clbc.2017.07.004

    authors： Batistatou A,Kotoula V,Bobos M,Kouvatseas G,Zagouri F,Tsolaki E,Gogas H,Koutras A,Pentheroudakis G,Timotheadou E,Pervana S,Goussia A,Petraki K,Sotiropoulou M,Koletsa T,Razis E,Kosmidis P,Aravantinos G,Papadimitriou C

    更新日期：2018-02-01 00:00:00

  • Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration.

    abstract：BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.3816/CBC.2009.n.008

    authors： Vogel VG,Qu Y,Wong M,Mitchell B,Mershon JL

    更新日期：2009-02-01 00:00:00

  • Magnetic resonance imaging-guided core needle breast biopsies resulting in high-risk histopathologic findings: upstage frequency and lesion characteristics.

    abstract：UNLABELLED:Analysis of magnetic resonance imaging-guided breast biopsies yielding high-risk histopathologic features at a single institution found an overall upstage rate to malignancy of 14% at surgical excision. All upstaged lesions were associated with atypical ductal hyperplasia. Flat epithelial atypia and atypical...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.12.005

    authors： Weinfurtner RJ,Patel B,Laronga C,Lee MC,Falcon SL,Mooney BP,Yue B,Drukteinis JS

    更新日期：2015-06-01 00:00:00

  • Kaposiform hemangioendothelioma of the breast in an adult female.

    abstract：:Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor that usually occurs in infants. It is commonly associated with Kasabach-Merritt syndrome and lymphangiomatosis. It generally originates on the skin, later affecting deeper tissue by infiltrative growth. Although visceral involvement is very u...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2011.03.008

    authors： Kim MG,Choi YS,Park SJ,Chong SM

    更新日期：2011-04-01 00:00:00

  • Management and Outcomes in Metaplastic Breast Cancer.

    abstract：:Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its manage...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2016.06.002

    authors： Tzanninis IG,Kotteas EA,Ntanasis-Stathopoulos I,Kontogianni P,Fotopoulos G

    更新日期：2016-12-01 00:00:00

  • The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer.

    abstract：BACKGROUND:There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2+ breast cancer (BC). The aim of this study was to assess the impact of local and systemic treatments on the outcome of patients diagnosed with BM from HER2+ BC over a period of 10 years, from 200...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2019.05.006

    authors： Gori S,Puglisi F,Moroso S,Fabi A,La Verde N,Frassoldati A,Tarenzi E,Garrone O,Vici P,Laudadio L,Cretella E,Turazza M,Foglietta J,Leonardi V,Cavanna L,Barni S,Galanti D,Russo A,Marchetti F,Valerio M,Lunardi G,Alo

    更新日期：2019-08-01 00:00:00

  • Ductal carcinoma in situ of the breast in men: a review.

    abstract：:Breast carcinoma in men is rare and comprises approximately 1% of all breast cancer cases. In contrast to the increase in the detection rate of ductal carcinoma in situ (DCIS) in women resulting from the wide use of screening mammography programs, the rate of male DCIS is still small and represents approximately 5% of...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2005.n.033

    authors： Pappo I,Wasserman I,Halevy A

    更新日期：2005-10-01 00:00:00

  • Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer.

    abstract：:Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with early-stage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2004.s.006

    authors： Mamounas EP,Geyer CE Jr,Swain SM

    更新日期：2004-01-01 00:00:00

  • Single Nucleotide Polymorphisms in the Acylphosphatase 2 Gene and The SNP-SNP Interactions on the Risk of Breast Cancer in Chinese Han Women.

    abstract：INTRODUCTION:The purpose of this study was to investigate the impact of single nucleotide polymorphisms (SNPs) in the acylphosphatase 2 gene and the SNP-SNP interactions on breast cancer (BC) risk in Chinese Han women. PATIENTS AND METHODS:A logistic regression model was used to examine the association between SNPs an...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.09.003

    authors： Wu J,Wang S,Liu F,Li S

    更新日期：2018-06-01 00:00:00

  • Isolated sternal involvement in breast cancer: is it truly stage IV disease?

    abstract：PURPOSE:There is no consensus regarding treatment for patients with breast cancer and isolated sternal involvement. Though classified as AJCC stage IV, this group of patients may have prolonged distant disease free survival. PATIENTS AND METHODS:Retrospective case series of 8 patients with isolated sternal recurrence....

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2011.03.017

    authors： Chockalingam P,Astrow AB,Klein P,Huang Y,Reichman BS,Citron ML

    更新日期：2011-06-01 00:00:00

  • Development and Validation of a Preoperative Scoring System to Distinguish Between Nonadvanced and Advanced Axillary Lymph Node Metastasis in Patients With Early-stage Breast Cancer.

    abstract：BACKGROUND:It has been determined that axillary lymph node dissection after the detection of limited axillary lymph node metastasis does not improve the prognosis of patients with breast cancer. Thus, a need exists for less-invasive axillary surgery. However, it remains unclear whether a predictive model based on preop...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.11.008

    authors： Murata T,Watase C,Shiino S,Jimbo K,Iwamoto E,Yoshida M,Takayama S,Suto A

    更新日期：2020-11-17 00:00:00

  • The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without Radiotherapy.

    abstract：BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.05.007

    authors： Escott CE,Zaenger D,Switchencko JM,Lin JY,Abugideiri M,Arciero CA,Pfister NT,Xu KM,Meisel JL,Subhedar P,Torres M,Curran WJ,Patel PR

    更新日期：2020-12-01 00:00:00

  • Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

    abstract：BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.04.008

    authors： Millis SZ,Gatalica Z,Winkler J,Vranic S,Kimbrough J,Reddy S,O'Shaughnessy JA

    更新日期：2015-12-01 00:00:00

  • Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?

    abstract：AIM:Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging. METHODS:Thirty-two breast cancer patients underwent both (18)F-FES and (18)F fluorodeoxyglucose...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2013.02.012

    authors： Yang Z,Sun Y,Zhang Y,Xue J,Wang M,Shi W,Zhu B,Hu S,Yao Z,Pan H,Zhang Y

    更新日期：2013-10-01 00:00:00

  • Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.

    abstract：BACKGROUND:To date, there have been no analyses to assess factors that influence post-mastectomy radiation therapy (PMRT) utilization in invasive lobular carcinoma (ILC) or to quantify the benefit of PMRT in ILC as compared with invasive ductal carcinoma (IDC). We compared histology-specific utilization of PMRT by tumo...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.02.001

    authors： Stecklein SR,Shen X,Mitchell MP

    更新日期：2016-08-01 00:00:00

  • Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

    abstract：:Preliminary results of a phase II study of gemcitabine plus trastuzumab in previously treated (up to 3 previous regimens) metastatic breast cancer patients are presented. Patients had histologically confirmed metastatic breast cancer, with 2+ or 3+ tumor HER2 expression. Treatment consisted of gemcitabine 1200 mg/m2 o...

    journal_title：Clinical breast cancer

    pub_type： 临床试验,杂志文章

    doi：10.3816/cbc.2002.s.004

    authors： O'Shaughnessy J,Vukelja SJ,Marsland T,Kimmel G,Ratnam S,Pippen J

    更新日期：2002-05-01 00:00:00

  • Clinicians Should Actively Promote Exercise in Survivors of Breast Cancer.

    abstract：:Breast cancer is the most common cancer affecting women, causing 29% of all female cancers and afflicting 14% of all female cancer-related deaths worldwide. It remains a significant clinical, psychological, and financial burden. Exercise has been suggested to reduce cancer recurrence and cancer-related mortality from ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.06.008

    authors： Kapila AK,Hamdi M,Patel A

    更新日期：2018-10-01 00:00:00

  • Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

    abstract：BACKGROUND:Letrozole withdrawal for 3 months might permit estrogenic stimulation in residual resistant breast cancer disease susceptible to letrozole reintroduction. We investigated the impact of a 3-month letrozole-free interval on serum estradiol levels in patients with early stage breast cancer. PATIENTS AND METHOD...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.03.007

    authors： Balduzzi A,Bagnardi V,Sandri MT,Dellapasqua S,Cardillo A,Montagna E,Cancello G,Iorfida M,Ghisini R,Viale G,Intra M,Luini A,Goldhirsch A,Colleoni M

    更新日期：2015-10-01 00:00:00

  • A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.

    abstract：PURPOSE:The purpose of this study is to determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC) and to search for a correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. PATIENTS AND ME...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2009.n.027

    authors： Yerushalmi R,Hayes MM,Gelmon KA,Chia S,Bajdik C,Norris B,Speers C,Hassell P,O'Reilly SE,Allan S,Shenkier TN

    更新日期：2009-08-01 00:00:00

  • BRCA mutations and the risk of angiosarcoma after breast cancer treatment.

    abstract：:Post-breast cancer treatment-related angiosarcomas were first observed in lymphedematous extremities after mastectomy and are now being reported with increasing frequency after lumpectomy and radiation. A case history is presented of a BRCA2 carrier who had a postmastectomy chest wall angiosarcoma but had neither ther...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2008.n.066

    authors： West JG,Weitzel JN,Tao ML,Carpenter M,West JE,Fanning C

    更新日期：2008-12-01 00:00:00

  • New horizons in treating metastatic disease.

    abstract：:The management of metastatic breast cancer is changing as a consequence of extraordinary discoveries in cancer research and the development of more advanced diagnostic technologies. Although traditional chemotherapeutics such as anthracyclines and taxanes still represent the mainstay of treatment for this disease, new...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2001.n.002

    authors： Cristofanilli M,Hortobagyi GN

    更新日期：2001-01-01 00:00:00

  • Use of Adjuvant Breast Hypofractionation Radiation Treatment at a Cancer Center in Ontario From 2011 to 2018.

    abstract：BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.03.006

    authors： Lam E,Chan S,Karam I,Lee J,Wong G,Zhang L,Vesprini D,Wronski M,Chin L,Razvi Y,McKenzie E,Rakovitch E,Chow E

    更新日期：2020-10-01 00:00:00

  • A Pilot Randomized Controlled Trial on the Effects of a Progressive Exercise Program on the Range of Motion and Upper Extremity Grip Strength in Young Adults With Breast Cancer.

    abstract：BACKGROUND:The diagnosis of breast cancer in young women (aged 18-45 years) has been increasing. Women are commonly left coping with treatment-related disabilities of the upper limb that can persist for > 2 years postoperatively. PATIENTS AND METHODS:A total of 59 young breast cancer patients (29 in the intervention g...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clbc.2017.06.007

    authors： Ibrahim M,Muanza T,Smirnow N,Sateren W,Fournier B,Kavan P,Palumbo M,Dalfen R,Dalzell MA

    更新日期：2018-02-01 00:00:00

  • Development of breast cancer in a 21-year-old childhood Wilms' tumor survivor with a BRCA1 2634delC mutation.

    abstract：:Breast cancer at age 21 is rare, even in individuals who have a genetic predisposition. These early diagnoses are usually the result of a hereditary cancer syndrome. Other contributing factors, such as chemotherapy and radiation for previous malignancies, can also increase the risk of secondary malignancies, including...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2010.11.001

    authors： Dulude AM,D'Souza J,Harrison N,Ramanathan RK

    更新日期：2011-08-01 00:00:00

  • Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.

    abstract：:More than 220,000 women will be diagnosed with breast cancer this year, and approximately 75% of these women will be long-term survivors of this disease. Survival has improved largely because of advances in adjuvant hormone therapy and chemotherapy, as well as early detection strategies. Because most women will receiv...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2007.s.003

    authors： Rugo HS

    更新日期：2007-07-01 00:00:00

  • Neoadjuvant endocrine therapy in primary breast cancer.

    abstract：:Neoadjuvant chemotherapy has been employed increasingly in operable breast cancer during recent years. Several randomized trials showed that the chances of breast conserving therapy are being enhanced, and that survival was not compromised by primary systemic therapy compared to adjuvant treatment. Apart from the surg...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2004.n.039

    authors： Huober J,Krainick-Strobel U,Kurek R,Wallwiener D

    更新日期：2004-12-01 00:00:00

  • CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

    abstract：BACKGROUND:This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) disease. METHODS:We ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clbc.2018.04.017

    authors： Deng Y,Ma G,Li W,Wang T,Zhao Y,Wu Q

    更新日期：2018-10-01 00:00:00